News & Updates

A recent study suggests a positive association between shift work and risk of kidney stone events, with lifestyle factors partially mediating the association.

In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.

Among prostate cancer patients receiving treatment with the androgen receptor pathway inhibitor (ARPI) apalutamide, those who also use statins appear to have longer overall survival, according to a study.